Head-to-head · Cost-Efficiency Index
Lean Rx vs MedLeanRx
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Lean Rx
Shoppers who don't need transparency on credentials before comparing headline prices.
Visit Lean RxMedLeanRx
Cost-first shoppers who want texas residents who want a named supervising physician and a brand-medication pathway alongside compounded options.
Visit MedLeanRxThe verdict
Lean Rx and MedLeanRx tie on the Cost-Efficiency Index at 58/100, so neither wins outright on the numbers. For most shoppers we'd start with Lean Rx (ranked #288, a hair above #289) — Shoppers who don't need transparency on credentials before comparing headline prices. But MedLeanRx is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Lean Rx.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Lean Rx | MedLeanRx |
|---|---|---|
| Cost-Efficiency Index | 58/100 | 58/100 |
| Semaglutide / mo | $266/mo (starting dose, compounded) | $149/mo (compounded oral) |
| Tirzepatide / mo | $399/mo (starting dose, compounded) | $269/mo (compounded) |
| Semaglutide / yr (modeled) | $3,192 | $1,788 |
| Tirzepatide / yr (modeled) | $4,788 | $3,228 |
| Coverage | Coverage not published | 1 state |
| Oral / sublingual | Yes | Yes |
| Brand-name access | Compounded only | Yes |
| Rank here | #288 | #289 |
Lean Rx
58/100Where the value is
- Offers both semaglutide and tirzepatide
- Simple, low headline starting prices
- Straightforward telehealth consultation flow described
The tradeoffs
- No LegitScript certification displayed anywhere on the site
- No named medical director or compounding pharmacy partner
MedLeanRx
58/100Where the value is
- Named supervising physician (Dr. Johnson Uzor, MD) publicly disclosed with a dedicated bio page
- Both compounded semaglutide (injectable and oral tablet) and a brand Wegovy/Zepbound/Foundayo pathway offered on one platform
- Flat pricing with no dose-tier escalation disclosed
The tradeoffs
- Texas only — not available in any other state
- Compounding pharmacy is never named anywhere on the site
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.